348 related articles for article (PubMed ID: 33796887)
1. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I
Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
[TBL] [Abstract][Full Text] [Related]
2. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
Marwah R; Xing D; Squire T; Soon YY; Gan HK; Ng SP
J Neurooncol; 2023 Sep; 164(3):505-524. PubMed ID: 37733174
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
4. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
7. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.
Conde-Moreno AJ; García-Gómez R; Albert-Antequera M; Almendros-Blanco P; De Las Peñas-Bataller R; González-Vidal V; López-Torrecilla JL; Ferrer-Albiach C
Rep Pract Oncol Radiother; 2015; 20(3):231-8. PubMed ID: 25949228
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
9. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
[TBL] [Abstract][Full Text] [Related]
10. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
Sahebjam S; Forsyth PA; Tran ND; Arrington JA; Macaulay R; Etame AB; Walko CM; Boyle T; Peguero EN; Jaglal M; Mokhtari S; Enderling H; Raghunand N; Gatewood T; Long W; Dzierzeski JL; Evernden B; Robinson T; Wicklund MC; Kim S; Thompson ZJ; Chen DT; Chinnaiyan P; Yu HM
Neuro Oncol; 2021 Apr; 23(4):677-686. PubMed ID: 33173935
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study.
Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E
Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269
[TBL] [Abstract][Full Text] [Related]
13. The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.
Chan J; Jayamanne D; Wheeler H; Khasraw M; Wong M; Kastelan M; Guo L; Back M
Clin Transl Radiat Oncol; 2020 May; 22():33-39. PubMed ID: 32195378
[TBL] [Abstract][Full Text] [Related]
14. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
15. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.
Attal J; Chaltiel L; Lubrano V; Sol JC; Lanaspeze C; Vieillevigne L; Latorzeff I; Cohen-Jonathan Moyal E
J Neurooncol; 2018 Jan; 136(2):413-419. PubMed ID: 29273890
[TBL] [Abstract][Full Text] [Related]
16. The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.
Kambe A; Kitao S; Ochiai R; Hosoya T; Fujii S; Kurosaki M
J Neurooncol; 2024 Jan; 166(1):175-183. PubMed ID: 38165552
[TBL] [Abstract][Full Text] [Related]
17. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
[TBL] [Abstract][Full Text] [Related]
18. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.
Back M; Gzell CE; Kastelan M; Guo L; Wheeler HR
Neurooncol Pract; 2015 Mar; 2(1):48-53. PubMed ID: 26034641
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
Klobukowski L; Falkov A; Chelimo C; Fogh SE
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]